Cargando…

TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity

BACKGROUND: The tumor microenvironment contains stromal cells, including endothelial cells and fibroblasts, that aid tumor growth and impair immune cell function. Many solid tumors remain difficult to cure because of tumor-promoting stromal cells, but current therapies targeting tumor stromal cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaminski, Michael F, Bendzick, Laura, Hopps, Rachel, Kauffman, Marissa, Kodal, Behiye, Soignier, Yvette, Hinderlie, Peter, Walker, Joshua T, Lenvik, Todd R, Geller, Melissa A, Miller, Jeffrey S, Felices, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516302/ https://www.ncbi.nlm.nih.gov/pubmed/36162918 http://dx.doi.org/10.1136/jitc-2022-004725

Ejemplares similares

NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
por: Vallera, Daniel A., et al.
Publicado: (2020)

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer
por: Kennedy, Philippa R., et al.
Publicado: (2023)

A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer
por: Vallera, Daniel A., et al.
Publicado: (2021)

Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer
por: Felices, Martin, et al.
Publicado: (2023)

Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion
por: Myers, Jacob A., et al.
Publicado: (2022)

Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy
por: Xie, Lin, et al.
Publicado: (2021)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
por: Cheng, Ying, et al.
Publicado: (2020)

Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression
por: Nelson, Adam, et al.
Publicado: (2022)

Targeting the tumor vasculature with TEM8-specific T cells
por: Williams, LaTerrica C, et al.
Publicado: (2014)

A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors
por: Floerchinger, Alessia, et al.
Publicado: (2023)

Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
por: Fabian, Kellsye P, et al.
Publicado: (2021)

Natural killer cells in pancreatic cancer stroma
por: Fincham, Rachel Elizabeth Ann, et al.
Publicado: (2021)

Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19
por: Osman, Mohammed, et al.
Publicado: (2020)

Cytokine-induced natural killer cell training is dependent on cellular metabolism and is defective in obesity
por: Kedia-Mehta, Nidhi, et al.
Publicado: (2021)

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
por: Reches, Adi, et al.
Publicado: (2020)

Adjuvant DNA vaccine pNMM promotes enhanced specific immunity and anti-tumor effects
por: Wang, Yu, et al.
Publicado: (2023)

Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186
por: Dettling, Danielle E, et al.
Publicado: (2022)

Circulating Tumor Cells: Who is the Killer?
por: Paterlini-Bréchot, Patrizia
Publicado: (2014)

Natural killer cells in tumor immunotherapy
por: Wang, Dongyao, et al.
Publicado: (2023)

Patient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers
por: Messaoudene, Meriem, et al.
Publicado: (2017)

IMMU-12. PHASE I/II TRIAL OF IMMUNOTHERAPY WITH FUSIONS OF DENDRITIC CELLS AND TUMOR CELLS FOR RELAPSED OR REFRACTORY BRAIN TUMORS IN CHILDREN AND YOUNG ADULTS
por: Yamaoka, Masayoshi, et al.
Publicado: (2020)

Profiling specific cell populations within the inflammatory tumor microenvironment by oscillating-gradient diffusion-weighted MRI
por: Hoffmann, Emily, et al.
Publicado: (2023)

Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma
por: Dean, Erin A., et al.
Publicado: (2023)

Combination Treatment with Irritant and Recombinant Interleukin 2 in the Peritoneal Cavity for Evoking Effective Anti‐tumor Activity: Generation of Lymphokine‐activated Killer Cells and Tumor‐specific Killer Cells
por: Uchida, Hiroyuki, et al.
Publicado: (1990)

Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review
por: Uppendahl, Locke D., et al.
Publicado: (2018)

T057: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
por: Lynch, Ryan C., et al.
Publicado: (2022)

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
por: Park, Jeong A, et al.
Publicado: (2023)

Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis
por: Perry, Lauren M, et al.
Publicado: (2023)

Off-the-shelf CAR–engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia
por: Mansour, Anthony G., et al.
Publicado: (2023)

Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers
por: Roche, Veronique, et al.
Publicado: (2023)

IMMU-17. Comprehensive immunological gene expression profiling of pediatric brain tumors
por: Levine, Adrian, et al.
Publicado: (2022)

Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell Engagers
por: Reusch, Uwe, et al.
Publicado: (2022)

Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy
por: Nikkhoi, Shahryar Khoshtinat, et al.
Publicado: (2023)

Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab
por: Routh, Eric D, et al.
Publicado: (2023)

IMMU-08. reMATCH PROTOCOL: PHASE II STUDY OF EX-VIVO EXPANDED AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (X-ALT) + TOTAL TUMOR RNA DC VACCINE (TT-RNA DC) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND PERIPHERAL BLOOD STEM CELL (PBSC) RESCUE OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) AND PBSC IN PATIENTS (PTS) WITH RECURRENT PNET (R-PNET)
por: Gururangan, Sridharan, et al.
Publicado: (2020)

Targeting Natural Killer Cells for Tumor Immunotherapy
por: Zhang, Cai, et al.
Publicado: (2020)

Natural Killer Cells: Tumor Surveillance and Signaling
por: Meza Guzman, Lizeth G., et al.
Publicado: (2020)

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
por: Dillman, Robert O., et al.
Publicado: (2023)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nhbk329c1s4ms9312rs1au81fs